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COST-UTILITY ANALYSIS OF ANTIDEPRESSANTS FOR SECOND-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER
Malone DC University of Arizona, Tucson, AZ, USA OBJECTIVES: This analysis estimated the cost-utility of secondline treatment for major depressive disorder using generic selective serotonin reuptake inhibitors (SSRIs), escitalopram, paroxetine CR, sertraline or venlafaxine XR. METHODS: A Markov probabilistic decision analysis was constructed with cycle dependent transition probabilities for persistency over 52 weeks, examining whether persistent patients would have a response, and if this response was followed by remission. Response was °Ý50% improvement from baseline in depression rating score. Remission was defined as °Ü7 HAM-D or °Ü10 MADRS. Remission and response rates were obtained from published clinical trials and entered into the model using beta distributions. Utilities were based on duration of treatment and changed weekly over the year. Baseline utility scores were 0.35, 0.21, and 0.30 for remission, response, and treatment failure, respectively; between days 56-365 utility scores were 0.85, 0.72, and 0.58, respectively. Wholesale acquisition costs were used for medication costs. Remission, response, and treatment failure costs were obtained from the literature and were estimated using gamma distributions. The analysis was conducted using 10,000 Monte Carlo simulations with first-and second-order sampling procedures. RESULTS: The lowest cost option was generic SSRI agents ($3283), with the highest being venlafaxine XR ($4111 3 Janssen Pharmaceutica N.V, Beerse, Belgium The major cost to the health care system in treating schizophrenia is hospital based care. To help estimate the cost of treating schizophrenia and to assess the effectiveness of treatment comprehensive data on rehospitalization rates are appropriate. OBJECTIVE: To conduct a systematic review of the literature on rehospitalization rates for schizophrenia. METHODS: Published clinical trials of antipsychotic medications and large representative naturalistic studies were systematically identified by conducting searches of the Cochrane Library Schizophrenia Group's Register and MEDLINE databases. Identified sources were supplemented with a reference search for additional relevant literature. Studies were included if they were published from 1990-2004 and reported 1-year rehospitalization rates among patients not hospitalized. This included (a) clinical trials of outpatients or of recent discharge patients; and (b) naturalistic cohorts followed after discharge from hospital. Hospitalization rates were adjusted based on the sample size. Studies were stratified based on the patient group treated. RESULTS: Patients after their first hospitalization for schizophrenia (first episode patients; n = 36,192) from case registries in 5 nations had an average annual readmission rate of 33% (range 15-55%). Of stable response patients, comparison between patients on first generation (conventional; n = 265) and second generation (novel; n = 628) antipsychotic regimes indicated that those on second generation were significantly less likely to be readmitted (Mean difference = 3.02; 95% CI = 1.75:4.29). Similarly, of patients treated for clinical exacerbation comparison between patients on first (n = 761) and second generation (n = 1141) regimes indicated that those on a second generation regime were significantly less likely to be readmitted (Mean difference = 5.07; 95% CI = 4.41:5.72). CONCLUSIONS: Rehospitalization rates were significantly lower for patients on second than first generation antipsychotics. This finding appears to be robust across patient groupings. The use of second generation antipsychotics may reduce the cost of care.
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